10 May 2018

National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU

Final Agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 18:00.

Please note that this agenda is final and is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 6 March 2018 – Part 1 only (open session)
  6. Appraisal of nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182] 
    • The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for nivolumab with ipilimumab for untreated metastatic renal cell carcinoma and as a consequence this discussion will take place in a Part 2 session (Part 2 sessions are closed to public observers).
    • 6.1. Declarations of interest – Part 2 only (closed session)
    • 6.2. Introduction – Part 2 only (closed session)
    • 6.3. Presentation – Part 2 only (closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of cabozantinib for untreated metastatic renal cell carcinoma [ID1208]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction – Part 1 only (open session)
    • 7.3. Presentation – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction – Part 1 only (open session)
    • 8.3. Presentation – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048]
    • 9.1. Declarations of interest – Part 1 only (open session)
    • 9.2. Introduction – Part 1 only (open session)
    • 9.3. Presentation – Part 1 AND part 2 (open and closed session)
    • 9.4. Agreement on the content of the Final Appraisal Determination (FAD) – Part 2 only (closed session)
  10. Appraisal of ocrelizumab for treating relapsing multiple sclerosis [ID937]
    • 10.1. Declarations of interest – Part 1 only (open session)
    • 10.2. Introduction – Part 1 only (open session)
    • 10.3. Presentation – Part 1 AND part 2 (open and closed session)
    • 10.4. Agreement on the content of the Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 6 June 2018, 10:00, National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on 25 April 2018Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Ana Uribe Echeverry.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 11 to 25 April 2018
Registration is closed.